Search

Your search keyword '"Johnson, Nathalie A."' showing total 790 results
Start Over Author "Johnson, Nathalie A."
790 results on '"Johnson, Nathalie A."'

201. Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

Author

Timmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth P., Keane, Colm, Tzoran, Inna, Vucinic, Vladan, Zinzani, Pier Luigi, Marceau West, Rachel, Pillai, Pallavi, Marinello, Patricia, and Herrera, Alex F.

Abstract

Background: Programmed cell death protein 1 (PD-1) inhibitors are a standard of care for relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL), but better treatment options are needed for patients with anti-PD-1-refractory disease. Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint receptor with a role in regulating T-cell function. Dual blockade of PD-1 and LAG-3 has demonstrated antitumor activity in patients with advanced melanoma. Combination therapy with favezelimab (anti-LAG-3) and pembrolizumab (anti-PD-1) is currently being investigated in a phase 1/2 study (NCT03598608) in patients with R/R hematologic malignancies. Prior analyses showed that the combination had antitumor activity and manageable safety in patients with heavily pretreated anti-PD-1-refractory cHL (cohort 2). Updated results for this cohort are presented.

Published
2023
Full Text
View/download PDF

202. Mixture Model to Predict the Cumulative Incidence of Relapses in Follicular Lymphoma : Need for Longer Follow-up or Alternative Outcomes

Author

Guidez, Stephanie, Glaisner, Sylvie, Van Den Neste, Eric, Gyan, Emmanuel, Marjanovic, Zora, Fornecker, Luc-Matthieu, Deconinck, Eric, Fabbro, Michel, Dorvaux, Veronique, Robu, Daniela, Yokoyama, Hisayuki, Johnson, Nathalie A., Cheung, Matthew C., Snauwaert, Sylvia, Casanova, María, Terui, Yasuhito, Yamamoto, Go, Choudhary, Yuvraj, Mace, Joseph Ronald, Quick, Donald P., Morschhauser, Franck, and Foucher, Yohann

Abstract

Background: The effectiveness of treatments in follicular lymphoma is evaluated by the reduction in the rate of recurrence. One of the methodological difficulties is related to the presence of competitive events such as death or second primary malignancies. The related cumulative incidence functions (CIF) are always estimated by using the non-parametric Aalen-Johansen estimator and the associated predictors by using the Fine and Gray approach or by considering a cause-specific Cox model. In the present study, we investigated if the use of a parametric mixture model would provide additional information on the interpretation of the impact of treatments in the management of follicular lymphoma.

Published
2023
Full Text
View/download PDF

203. mRNA Translation Inhibition Targets Bioenergetic Homeostasis in AML Cells in Vitroand In Vivoand Synergizes with Cytarabine and Venetoclax

Author

Gife, Victor, Fooks, Katie, Berthelemy, Jules, Schcolnik-Cabrera, Alejandro, Galicia-Vazquez, Gabriela, Nouhi, Zaynab, Aloyz, Raquel, Rys, Ryan N, Johnson, Nathalie A., Mercier, Francois E., and Hulea, Laura

Abstract

Acute myeloid leukemia (AML) is an aggressive hematological cancer resulting from uncontrolled proliferation of differentiation-blocked myeloid cells. Seventy percent of AML patients are currently not cured with available treatments, highlighting the need of novel therapeutic strategies. Recently, inhibition of BCL-2 with venetoclax in combination with hypomethylating agents has emerged as an attractive strategy for high-risk AML cases. Another promising target in AML is the mammalian target of rapamycin complex 1 (mTORC1) (Oki et al, Nature Comm, 2021). However, clinical inhibition of mTORC1 is limited by its reactivation through compensatory and regulatory feedback loops. To curtail these drawbacks, we adopted a strategy of inhibiting an important effector of the mTORC1 signaling pathway controlling mRNA translation - the eukaryotic initiation factor 4A (eIF4A), subunit of the translation initiation complex eIF4F.

Published
2023
Full Text
View/download PDF

204. Safety and Preliminary Efficacy of Sabestomig (AZD7789), an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Previously Treated with Anti-PD-(L)1 Therapy

Author

Mei, Matthew G., Corazzelli, Gaetano, Morschhauser, Frank, Phillips, Elizabeth, Collins, Graham P., Lee, Hun Ju, Ansell, Steve M, Moskowitz, Craig H., Johnson, Nathalie A., Kuruvilla, John, Hutchings, Martin, Terol Castera, María José, Hawkins, George, Vossenkaemper, Anna, Collins, Teresa, Lesley, Robin, Dean, Emma, Yu, Ting, Hall, Connor, Cerec, Virginie, and Zinzani, Pier Luigi

Abstract

Background

Published
2023
Full Text
View/download PDF

205. Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study

Author

Moskowitz, Craig H., Zinzani, Pier Luigi, Fanale, Michelle A., Armand, Philippe, Johnson, Nathalie A., Radford, John A., Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Gustafson, Eric, Zhang, Yinghua, Ricart, Alejandro Daniel, Balakumaran, Arun, Chen, Robert W., Moskowitz, Craig H., Zinzani, Pier Luigi, Fanale, Michelle A., Armand, Philippe, Johnson, Nathalie A., Radford, John A., Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Gustafson, Eric, Zhang, Yinghua, Ricart, Alejandro Daniel, Balakumaran, Arun, and Chen, Robert W.

Published
2016

206. P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT.

Author

Timmerman, John, Lavie, David, Johnson, Nathalie, Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth, Keane, Colm, Tzoran, Inna, Vucinic, Vladan, Luigi Zinzani, Pier, Marceau West, Rachel, Pillai, Pallavi, Marinello, Patricia, and Herrera, Alex F.

Published
2023
Full Text
View/download PDF

207. P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA.

Author

Johnson, Nathalie, Lavie, David, Borchmann, Peter, Gregory, Gareth, Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Marceau West, Rachel, Pillai, Pallavi, Marinello, Patricia, and Timmerman, John

Published
2023
Full Text
View/download PDF

210. Breast Cancer Survivorship: Why, What and When?

Author

Gass, Jennifer, primary, Dupree, Beth, additional, Pruthi, Sandhya, additional, Radford, Diane, additional, Wapnir, Irene, additional, Antoszewska, Reza, additional, Curtis, Audrey, additional, and Johnson, Nathalie, additional

Published
2016
Full Text
View/download PDF

212. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma

Author

Assouline, Sarit E., primary, Nielsen, Torsten Holm, additional, Yu, Stephen, additional, Alcaide, Miguel, additional, Chong, Lauren, additional, MacDonald, David, additional, Tosikyan, Axel, additional, Kukreti, Vishal, additional, Kezouh, Abbas, additional, Petrogiannis-Haliotis, Tina, additional, Albuquerque, Marco, additional, Fornika, Daniel, additional, Alamouti, Sepideh, additional, Froment, Remi, additional, Greenwood, Celia M. T., additional, Oros, Kathleen Klein, additional, Camglioglu, Errol, additional, Sharma, Ayushi, additional, Christodoulopoulos, Rosa, additional, Rousseau, Caroline, additional, Johnson, Nathalie, additional, Crump, Michael, additional, Morin, Ryan D., additional, and Mann, Koren K., additional

Published
2016
Full Text
View/download PDF

213. Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study.

Author

Chen, Robert W., primary, Zinzani, Pier Luigi, additional, Fanale, Michelle A., additional, Armand, Philippe, additional, Johnson, Nathalie, additional, Ribrag, Vincent, additional, Radford, John A., additional, Tomita, Akihiro, additional, Shipp, Margaret Ann, additional, Wang, Yang, additional, Ricart, Alejandro Daniel, additional, Balakumaran, Arun, additional, and Moskowitz, Craig H., additional

Published
2016
Full Text
View/download PDF

214. Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors

Author

Dupéré-Richer, Daphné, primary, Kinal, Mena, additional, Pettersson, Filippa, additional, Emond, Audrey, additional, Calvo-Vidal, M. Nieves, additional, Nichol, Jessica N., additional, Guilbert, Cynthia, additional, Plourde, Dany, additional, Klein Oros, Kathleen, additional, Nielsen, Torsten H., additional, Ezponda, Teresa, additional, Licht, Jonathan D., additional, Johnson, Nathalie A., additional, Assouline, Sarit, additional, Cerchietti, Leandro, additional, Miller, Wilson H., additional, and Mann, Koren K., additional

Published
2016
Full Text
View/download PDF

215. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL

Author

Savage, Kerry J., primary, Slack, Graham W., additional, Mottok, Anja, additional, Sehn, Laurie H., additional, Villa, Diego, additional, Kansara, Roopesh, additional, Kridel, Robert, additional, Steidl, Christian, additional, Ennishi, Daisuke, additional, Tan, King L., additional, Ben-Neriah, Susana, additional, Johnson, Nathalie A., additional, Connors, Joseph M., additional, Farinha, Pedro, additional, Scott, David W., additional, and Gascoyne, Randy D., additional

Published
2016
Full Text
View/download PDF

217. Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas

Author

Morin, Ryan D., primary, Assouline, Sarit, additional, Alcaide, Miguel, additional, Mohajeri, Arezoo, additional, Johnston, Rebecca L., additional, Chong, Lauren, additional, Grewal, Jasleen, additional, Yu, Stephen, additional, Fornika, Daniel, additional, Bushell, Kevin, additional, Nielsen, Torsten Holm, additional, Petrogiannis-Haliotis, Tina, additional, Crump, Michael, additional, Tosikyan, Axel, additional, Grande, Bruno M., additional, MacDonald, David, additional, Rousseau, Caroline, additional, Bayat, Maryam, additional, Sesques, Pierre, additional, Froment, Remi, additional, Albuquerque, Marco, additional, Monczak, Yury, additional, Oros, Kathleen Klein, additional, Greenwood, Celia, additional, Riazalhosseini, Yasser, additional, Arseneault, Madeleine, additional, Camlioglu, Errol, additional, Constantin, André, additional, Pan-Hammarstrom, Qiang, additional, Peng, Roujun, additional, Mann, Koren K., additional, and Johnson, Nathalie A., additional

Published
2016
Full Text
View/download PDF

219. A Randomized, Phase II Study with Biomarker Analysis of Panobinostat with or without Rituximab in Relapsed Diffuse Large B Cell Lymphoma

Author

Assouline, Sarit, primary, Crump, Michael, additional, Holm Nielsen, Torsten, additional, Alcaide, Miguel, additional, Macdonald, David, additional, Tosikyan, Axel, additional, Haliotis, Tina, additional, Greenwood, Celia, additional, Klein Oros, Kathleen, additional, Morin, Ryan, additional, Johnson, Nathalie, additional, and Mann, Koren Kathleen, additional

Published
2015
Full Text
View/download PDF

220. Ethical Considerations of Medical Photography in the Management of Breast Disease.

Author

Nguyen, Toan T., VanderWalde, Lindi, Bellavance, Emily, Eisenhauer, Thomas, Hieken, Tina, Johnson, Nathalie, Kaufman, David I., O’Neill, Jennifer, Patten, Caitlin R., Teller, Paige, Tevis, Sarah, Sarantou, Terry, and Throckmorton, Alyssa

Abstract

Background: Medical photography has become an important component of the evaluation and management of patients across many specialties. It is increasingly utilized in contemporary practice with modern smartphones and enhanced digital media. Photography can enhance and improve treatment plans and communication between providers and patients. Additionally, photography supplements education, research, and marketing in both print and social media. Ethical and medicolegal standards for medical photography, specifically for patients with breast disease, have not been formally developed to guide medical providers.Purpose: To provide guidelines for breast care physicians using medical photography, the Ethics Committee of the American Society of Breast Surgeons presents an updated review of the literature and recommendations for ethical and practical use of photography in patient care.Methods: An extensive PubMed review of articles in English was performed to identify studies and articles published prior to 2018 investigating the use of medical photography in patient care and the ethics of medical photography. After review of the literature, members of the Ethics Committee convened a panel discussion to identify best practices for the use of medical photography in the breast care setting. Results of the literature and panel discussion were then incorporated to provide the content of this article.Conclusion: The Ethics Committee of the American Society of Breast Surgeons acknowledges that photography of the breast has become an invaluable tool in the delivery of state-of-the-art care to our patients with breast disease, and we encourage the use of this important medium. Physicians must be well informed regarding the concerns associated with medical photography of the breast to optimize its safe and ethical use in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

221. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Author

Chen, Robert, Zinzani, Pier Luigi, Lee, Hun Ju, Armand, Philippe, Johnson, Nathalie A., Brice, Pauline, Radford, John, Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Lin, Jianxin, Kim, Eunhee, Nahar, Akash, Balakumaran, Arun, and Moskowitz, Craig H.

Abstract

Programmed death-1 inhibitors are approved for patients with relapsed or refractory classic Hodgkin lymphoma (RRcHL). We present the 2-year follow-up of the phase 2 KEYNOTE-087 study of pembrolizumab in 210 patients, based on HL progression after autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV; cohort 1); salvage chemotherapy and BV, with ineligibility for SCT owing to chemorefractory disease (cohort 2); and progression after SCT without BV (cohort 3). With a median follow-up of 27.6 months, the objective response rate (ORR) by blinded independent central review was 71.9% (95% CI, 65.3-77.9), the complete response rate (CRR) was 27.6%, and the partial response (PR) rate was 44.3%. Median duration of response was 16.5 months (range, 0.0+ to 27.0+ [+, no progressive disease at last assessment]) in all patients, 22.1 months in cohort 1, 11.1 months in cohort 2, and 24.4 months in cohort 3. Median progression-free survival was not reached in all patients with CR: 13.8 months (95% CI, 12.0-22.1) for patients with PR and 10.9 months (95% CI, 5.6-11.1) for patients with stable disease. Median overall survival was not reached in all patients or in any cohort. Treatment-related adverse events (TRAEs) of any grade occurred in 153 (72.9%) patients; grades 3 and 4 occurred in 25 (12.0%) patients; none resulted in death. Results confirmed effective antitumor activity, durability of response, and manageable safety of pembrolizumab monotherapy in RRcHL, regardless of prior treatment and including chemoresistant cHL. This trial was registered at www.clinicaltrials.gov as #NCT02453594.

Published
2019
Full Text
View/download PDF

225. The Ethics of Breast Surgery

Author

Throckmorton, Alyssa, primary, VanderWalde, Lindi, additional, Brackett, Craig, additional, Dominici, Laura, additional, Eisenhauer, Thomas, additional, Johnson, Nathalie, additional, Kong, Amanda, additional, Ludwig, Kandice, additional, O’Neill, Jennifer, additional, Pugliese, Matthew, additional, Teller, Paige, additional, and Sarantou, Terry, additional

Published
2015
Full Text
View/download PDF

228. An RCOR1 loss–associated gene expression signature identifies a prognostically significant DLBCL subgroup

Author

Chan, Fong Chun, primary, Telenius, Adele, additional, Healy, Shannon, additional, Ben-Neriah, Susana, additional, Mottok, Anja, additional, Lim, Raymond, additional, Drake, Marie, additional, Hu, Sandy, additional, Ding, Jiarui, additional, Ha, Gavin, additional, Scott, David W., additional, Kridel, Robert, additional, Bashashati, Ali, additional, Rogic, Sanja, additional, Johnson, Nathalie, additional, Morin, Ryan D., additional, Rimsza, Lisa M., additional, Sehn, Laurie, additional, Connors, Joseph M., additional, Marra, Marco A., additional, Gascoyne, Randy D., additional, Shah, Sohrab P., additional, and Steidl, Christian, additional

Published
2015
Full Text
View/download PDF

229. Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients

Author

Lim, Emilia L, primary, Trinh, Diane L, additional, Scott, David W, additional, Chu, Andy, additional, Krzywinski, Martin, additional, Zhao, Yongjun, additional, Robertson, A Gordon, additional, Mungall, Andrew J, additional, Schein, Jacqueline, additional, Boyle, Merrill, additional, Mottok, Anja, additional, Ennishi, Daisuke, additional, Johnson, Nathalie A, additional, Steidl, Christian, additional, Connors, Joseph M, additional, Morin, Ryan D, additional, Gascoyne, Randy D, additional, and Marra, Marco A, additional

Published
2015
Full Text
View/download PDF

230. Identification of novel prognostic biomarkers in diffuse large B cell lymphoma in the rituximab era

Author

Johnson, Nathalie

Subjects
immune system diseases, hemic and lymphatic diseases
Abstract

Diffuse large B cell lymphoma (DLBCL) is the most common form of lymphoma and is characterized by marked clinical and genetic heterogeneity. Approximately 60% of patients with DLBCL are cured with multi-agent chemotherapy consisting of rituximab, cyclophosphamide, hydroxyldaunomycin, oncovin and prednisone (R-CHOP). R-CHOP represents the current standard of care throughout the world for the treatment of DLBCL. The international prognostic index (IPI) is a clinical tool that can help risk-stratify patients at the time of diagnosis but it fails to identify 50% of patients who will relapse and provides no insights into the biology of the disease. The aim of this work was to identify prognostic markers that would complement the IPI, would reflect the underlying tumour biology and could be easily translated into the clinical setting. We used flow cytometry (FCM) to study the protein expression of the CD20 antigen, the target of rituximab on lymphoma cells and performed fluorescence in situ hybridization on DLBCL biopsies to identify the presence of genomic rearrangements in the BCL2 and MYC oncogenes. We also used DNA sequencing to determine if somatic mutations involving the rituximab binding epitope of CD20 had any impact upon patients failing therapy. We determined that recurrent mutations of exon 5 of CD20 do not explain rituximab resistance in clinical cases of DLBCL. In contrast, we could demonstrate that both a reduced expression of CD20 by FCM and the presence of concurrent de-regulation of MYC and BCL2 expression are independently associated with an inferior survival in DLBCL patients treated with R-CHOP. Importantly, both maintain their prognostic significance in multivariate analysis, independent of the IPI. Furthermore, these biomarkers reveal important novel insights into DLBCL biology and provide rational targets for therapy. As such they should be investigated and validated prospectively for future use in the clinical setting.

Published
2010
Full Text
View/download PDF

231. The Impact of Concurrent MYC BCL2 Protein Expression on the Risk of Secondary Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma (DLBCL)

Author

Savage, Kerry J., primary, Sehn, Laurie H., additional, Villa, Diego, additional, Kansara, Roopesh R., additional, Mottok, Anja, additional, Ennishi, Daisuke, additional, Ben-Neriah, Susana, additional, Kridel, Robert, additional, Steidl, Christian, additional, Tan, King L., additional, Johnson, Nathalie, additional, Slack, Graham W., additional, Connors, Joseph M., additional, Farinha, Pedro, additional, Scott, David W., additional, and Gascoyne, Randy D., additional

Published
2014
Full Text
View/download PDF

232. FAS Mutations Accelerate Lymphoma Growth and Induce Therapeutic Resistance

Author

Totten, Stephanie, primary, Gaucher, Denis, additional, Morin, Ryan D, additional, Assouline, Sarit, additional, Connors, Joseph M., additional, Marra, Marco A., additional, Scott, David W., additional, Gascoyne, Randy D., additional, Pelletier, Jerry, additional, Mann, Koren K, additional, and Johnson, Nathalie, additional

Published
2014
Full Text
View/download PDF

233. Methods for Sample Acquisition and Processing of Serial Blood and Tumor Biopsies for Multicenter Diffuse Large B-cell Lymphoma Clinical Trials

Author

Nielsen, Torsten Holm, primary, Diaz, Zuanel, additional, Christodoulopoulos, Rosa, additional, Charbonneau, Fredrick, additional, Qureshi, Samia, additional, Rousseau, Caroline, additional, Benlimame, Naciba, additional, Camlioglu, Errol, additional, Constantin, André Marc, additional, Oros, Kathleen Klein, additional, Krumsiek, Jan, additional, Crump, Michael, additional, Morin, Ryan D., additional, Cerchietti, Leandro, additional, Johnson, Nathalie A., additional, Petrogiannis-Haliotis, Tina, additional, Miller, Wilson H., additional, Assouline, Sarit E., additional, and Mann, Koren K., additional

Published
2014
Full Text
View/download PDF

234. CrebbpMutations Are Associated with Shorter Time to Progression in Limited-Stage Follicular Lymphoma Treated with Radiation

Author

Hershenfeld, Samantha A, Shelton, Victoria, Bakhtiari, Mehran, Calvente, Lourdes, Lajkosz, Katherine, Isaev, Keren, Silva, Anjali, Liu, Ting, Brodtkorb, Marianne, d'Amore, Francesco Annibale, Ludvigsen, Maja, Madsen, Charlotte, Hamilton-Dutoit, Stephen, Gandhi, Maher, Tobin, Joshua W.D., Baetz, Tara, LeBrun, David, Johnson, Nathalie A., Mungall, Andrew J., Crump, Michael, Delabie, Jan, Gospodarowicz, Mary, Hodgson, David, Hong, Michael, Kukreti, Vishal, Kuruvilla, John, Prica, Anca, Tremblay-Lemay, Rosemarie, Tsang, Richard, and Kridel, Robert

Published
2022
Full Text
View/download PDF

235. Recurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL

Author

Rushton, Christopher K, Rys, Ryan N, Chavez, Elizabeth, Hilton, Laura K, Alcaide, Miguel, Dreval, Kostiantyn, Cheung, Matthew, Cruz, Manuela, Coyle, Krysta M., Meissner, Barbara, Ben-Neriah, Susana, Michaud, Neil R., Daigle, Scott, Davidson, Jordan, Wong, Jasper, Hay, Annette E., Jain, Michael D., Shepherd, Lois E., Marra, Marco A., Kuruvilla, John, Crump, Michael, Mann, Koren Kathleen, Assouline, Sarit, Steidl, Christian, Scott, David W., Johnson, Nathalie A., and Morin, Ryan D.

Published
2022
Full Text
View/download PDF

236. Crebbp Mutations Are Associated with Shorter Time to Progression in Limited-Stage Follicular Lymphoma Treated with Radiation

Author

Hershenfeld, Samantha A, Shelton, Victoria, Bakhtiari, Mehran, Calvente, Lourdes, Lajkosz, Katherine, Isaev, Keren, Silva, Anjali, Liu, Ting, Brodtkorb, Marianne, d'Amore, Francesco Annibale, Ludvigsen, Maja, Madsen, Charlotte, Hamilton-Dutoit, Stephen, Gandhi, Maher, Tobin, Joshua W.D., Baetz, Tara, LeBrun, David, Johnson, Nathalie A., Mungall, Andrew J., Crump, Michael, Delabie, Jan, Gospodarowicz, Mary, Hodgson, David, Hong, Michael, Kukreti, Vishal, Kuruvilla, John, Prica, Anca, Tremblay-Lemay, Rosemarie, Tsang, Richard, and Kridel, Robert

Published
2022
Full Text
View/download PDF

237. Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements.

Author

Sesques, Pierre and Johnson, Nathalie A.

Subjects
*LYMPHOMA diagnosis, *LYMPHOMA treatment, *DEFENSIVE medicine, *MEDICAL screening, *DECISION making in clinical medicine, *FLUORESCENCE in situ hybridization
Abstract

High-grade B-cell lymphomas (HGBLs) with MYC and BCL2 and/or BCL6 rearrangements, so-called "double-hit" lymphomas (HGBL-DH), are aggressive lymphomas that form a separate provisional entity in the 2016 revised World Health Organization Classification of Lymphoid Tumors. Fluorescence in situ hybridization (FISH) will be required to identify HGBL-DH and will reclassify a subset of diffuse large B-cell lymphomas (DLBCLs) and HGBLs with features intermediate between DLBCL and Burkitt lymphoma into this new category. Identifying patients with HGBL-DH is important because it may change clinical management. This poses a challenge for centers that may not be ready to handle the additional workload and financial burden associated with the increase in requests for FISH testing. Herein, we review the mechanisms of deregulation of these oncogenes. We identify the factors associated with a poor prognosis and those that can guide diagnostic testing. Restricting FISH analysis to the 10% of DLBCL patients who have a germinal center B-cell phenotype and coexpress MYC and BCL2 proteins would be cost-effective and would identify the subset of patients who are at highest risk of experiencing a relapse following conventional therapy. These patients may benefit from intensified chemotherapy regimens or, ideally, should enroll in clinical trials investigating novel regimens. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

238. Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.

Author

Dupéré-Richer, Daphné, Kinal, Mena, Pettersson, Filippa, Emond, Audrey, Calvo-Vidal, M. Nieves, Nichol, Jessica N., Guilbert, Cynthia, Plourde, Dany, Klein Oros, Kathleen, Nielsen, Torsten H., Ezponda, Teresa, Licht, Jonathan D., Johnson, Nathalie A., Assouline, Sarit, Cerchietti, Leandro, Miller, Wilson H., and Mann, Koren K.

Subjects
GENE expression, HISTONE deacetylase inhibitors, DRUG resistance, TRANSMISSION electron microscopy, ENDOPLASMIC reticulum, B cells, CELL membranes
Abstract

The article discusses a study which examined gene expression changes associated with resistance to histone deacetylase inhibitors (HDACi). The study used a model of HDACi-resistance, vorinostat-resistant U937 cells in order to define the changes. The researchers performed transmission electron microscopy (EM) of endoplasmic reticulum (ER) in U937-B8 cells. The results found increased expression of the majority of the ER membrane annotated genes in the cells and HDACi-resistant clone U937-X.

Published
2017
Full Text
View/download PDF

240. Abstract 5538: Development of HDACi resistance in DLBCL leads to a switch in subtype towards a more differentiated B-cell and is associated with increased sensitivity to proteasome inhibition

Author

Dupéré-Richer, Daphné, primary, Kinal, Mena, additional, Pettersson, Filippa, additional, Hassawi, Mona, additional, ShaoNing, Yang, additional, Nielsen, Torsten H., additional, Klein, Kathleen, additional, Ezponda-Itoiz, Teresa, additional, Licht, Jonathan D., additional, Johnson, Nathalie, additional, Assouline, Sarit E., additional, Cerchietti, Leandro, additional, Miller, Wilson H., additional, and Mann, Koren K., additional

Published
2014
Full Text
View/download PDF

243. Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes

Author

Chambwe, Nyasha, primary, Kormaksson, Matthias, additional, Geng, Huimin, additional, De, Subhajyoti, additional, Michor, Franziska, additional, Johnson, Nathalie A., additional, Morin, Ryan D., additional, Scott, David W., additional, Godley, Lucy A., additional, Gascoyne, Randy D., additional, Melnick, Ari, additional, Campagne, Fabien, additional, and Shaknovich, Rita, additional

Published
2014
Full Text
View/download PDF

244. Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation

Author

O'Shea, Derville, O'Riain, Ciarán, Gupta, Manu, Waters, Rachel, Yang, Youwen, Wrench, David, Gribben, John, Rosenwald, Andreas, Ott, German, Rimsza, Lisa M., Holte, Harald, Cazier, Jean-Baptiste, Johnson, Nathalie A., Campo, Elias, Chan, Wing C., Gascoyne, Randy D., Young, Bryan D., Staudt, Louis M., Lister, T. Andrew, and Fitzgibbon, Jude

Published
2009
Full Text
View/download PDF

246. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing

Author

Morin, Ryan D., primary, Mungall, Karen, additional, Pleasance, Erin, additional, Mungall, Andrew J., additional, Goya, Rodrigo, additional, Huff, Ryan D., additional, Scott, David W., additional, Ding, Jiarui, additional, Roth, Andrew, additional, Chiu, Readman, additional, Corbett, Richard D., additional, Chan, Fong Chun, additional, Mendez-Lago, Maria, additional, Trinh, Diane L., additional, Bolger-Munro, Madison, additional, Taylor, Greg, additional, Hadj Khodabakhshi, Alireza, additional, Ben-Neriah, Susana, additional, Pon, Julia, additional, Meissner, Barbara, additional, Woolcock, Bruce, additional, Farnoud, Noushin, additional, Rogic, Sanja, additional, Lim, Emilia L., additional, Johnson, Nathalie A., additional, Shah, Sohrab, additional, Jones, Steven, additional, Steidl, Christian, additional, Holt, Robert, additional, Birol, Inanc, additional, Moore, Richard, additional, Connors, Joseph M., additional, Gascoyne, Randy D., additional, and Marra, Marco A., additional

Published
2013
Full Text
View/download PDF

248. Abstract 64: Quality and feasibility of a protocol for simultaneous isolation of RNA, DNA and tissue for IHC from needle core lymph node biopsies in DLBCL adapted for multi-center trials.

Author

Nielsen, Torsten H., primary, Diaz, Zuanel, additional, Christodoulopoulos, Rosa, additional, Yao, Lu, additional, Qureshi, Samia, additional, Benlimame, Naciba, additional, Camlioglu, Errol, additional, Crump, Michael, additional, Morin, Ryan D., additional, Johnson, Nathalie, additional, Haliotis, Tina P., additional, Miller, Wilson H., additional, Assouline, Sarit, additional, and Mann, Koren K., additional

Published
2013
Full Text
View/download PDF

249. Colorimetric In Situ Hybridization Identifies MYC Gene Signal Clusters Correlating With Increased Copy Number, mRNA, and Protein in Diffuse Large B-Cell Lymphoma

Author

Valentino, Carlo, primary, Kendrick, Samantha, additional, Johnson, Nathalie, additional, Gascoyne, Randy, additional, Chan, Wing C., additional, Weisenburger, Dennis, additional, Braziel, Rita, additional, Cook, James R., additional, Tubbs, Raymond, additional, Campo, Elias, additional, Rosenwald, Andreas, additional, Ott, German, additional, Delabie, Jan, additional, Jaffe, Elaine, additional, Zhang, Wenjun, additional, Brunhoeber, Patrick, additional, Nitta, Hiro, additional, Grogan, Tom, additional, and Rimsza, Lisa, additional

Published
2013
Full Text
View/download PDF

250. Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity

Author

De, Subhajyoti, primary, Shaknovich, Rita, additional, Riester, Markus, additional, Elemento, Olivier, additional, Geng, Huimin, additional, Kormaksson, Matthias, additional, Jiang, Yanwen, additional, Woolcock, Bruce, additional, Johnson, Nathalie, additional, Polo, Jose M., additional, Cerchietti, Leandro, additional, Gascoyne, Randy D., additional, Melnick, Ari, additional, and Michor, Franziska, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results